Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open firm
Fri, 28 Nov 09:30 am

The major Asian stock markets have opened the day on mixed note with Korea (down 0.3%) and Hong Kong (down 0.1%) leading the losses. However, stock markets in Japan (up 1.1%) and China (up 0.7%) have opened on a positive note. Oil-related shares and oil-linked currencies all tumbled in Asia, on the back of OPEC refraining from cutting output despite a huge over supply.

The Indian share markets have opened the day on a firm note ahead of September quarter GDP data. Majority of sectoral indices have opened in green with banking and consumer durable stocks leading among gainers.

The Sensex today is up by around 294 points (1.04%), while the NSE-Nifty is up by about 91 points (1.06%). BSE Mid Cap index is up by 0.96% and BSE Small Cap index up by around 0.88% The rupee is currently trading at Rs 61.82 to the US dollar.

Most of the Telecom stocks have opened the day on a positive note, with ACG network and Himachal Futuristic being the leading gainers in the pack. As per a financial daily, the two telecom giants viz., Bharti Airtel and Reliance Communications are offering competitive prices on data packages. Reportedly, Reliance Communications has offered a data plan where data usage at a monthly rental of Rs 999 with no download quantity caps. This move comes barely 24 hours after Bharti Airtel where the company would offer 4G services at or below 3G rates.

Most of the Indian pharma stocks have opened the day on a positive note, with Strides Acrolab and Wockhardt Ltd being the leading gainers in the pack. As per a leading financial daily, Hyderabad based Dr Reddy's Laboratories, has built a strong US drug pipeline. This will be an important driver for the company's revenues. The company has recently benefitted from Valcyte drug in the US market. Another such low competition drug is Sirolimus. On the other hand the company's injectables portfolio looks quite lucrative. Thus, Dr Reddy's US pipeline indicate a healthy growth trend. On the negative side, the company had received some 483s on its API facility. While these are minor observations, however increase in such instances can impact the company.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.